IL-6 Transmitter Signal Blockade Attenuates Systemic Sclerosis as Simulated in Mice Model
Qian Wang,Wenjing Ye,Fangfang Chen,Minrui Liang,Weiguo Wan,Wenyu Guo,Hejian Zou,Yu Xue
DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.20233706.299
2023-01-01
Journal of biological regulators and homeostatic agents
Abstract:Background: Cytokine interleukin (IL)-6 is involved in the development of systemic sclerosis (SSc). IL-6 forms a complex with soluble IL-6 receptor (sIL-6R), which binds to gp130 and initiates the transmitter signal for pro-inflammatory effects. TJ301 (sgp130-Fc or olamkicept) binds to IL-6-sIL-6R complex, reducing IL-6-sIL-6R binding to gp130 and inhibiting the transmitter signal. The aim of this study was to determine whether TJ301 can be used to treat SSc by inhibiting the IL-6 transmitter signal. Methods: Wild-type C57BL/6 mice were randomly distributed into experimental and control groups. Mice were injected subcutaneously with bleomycin (BLM, saline in the control group) for 28 days to induce SSc. Meanwhile, MR16-1, saline and TJ301 (saline in the control group) were separately injected to mice. On day 29, IL-6 and IL6R & alpha; levels of blood, skin and lung tissues histological analysis, and collagen I, CD31 and & alpha;-smooth muscle actin (& alpha;-SMA) of skin tissue expression were determined. The human foreskin fibroblast (HFF-1) cells and human dermal microvascular endothelial cells (HDMEC) were treated using transforming growth factor (TGF)-& beta;1, with or without TJ301. For HFF-1 cells, cell viability, IL-6 and IL-6R & alpha; levels and collagen I and & alpha;SMA expression were determined. For HDMEC, migration rate, IL-6 and IL-6R & alpha; levels, & alpha;SMA and CD31 expression and endothelial-to-mesenchymal transition (EndoMT) were detected. Results: Higher concentrations of IL-6 and sIL-6R were found in BLMtreated animals' blood. Additionally, their skin and lungs exhibited greater collagen accumulation and myofibroblasts that were positive for & alpha;-SMA. Inflammation level, immune cells that entered quantity, and profibrotic genes expression in skin and lung tissues were all reduced when TJ301 was used to block IL-6 transmitter signal. When triggered by TGF-1 in the lab, TJ301 may prevent dermal fibroblast and microvascular endothelial cells from expanding and migrating. Conclusions: Using TJ301 to inhibit the IL-6 transmitter signal may be a novel approach to treat SSc.